Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q4 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $8.2 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.

Earnings